Primary Care

General Hepatology

Questions discussed in this category

How do you choose between resmetirom and semaglutide in the treatment of MASH?

Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?

1 Answer available

How do people approach non-HIV patients with hepatitis B, a negative Hepatitis B E antigen, normal LFTs and relatively low HBV DNA between 2000-20000?

2 Answers available

How do you determine the optimal time to restart a diuretic in a patient with cirrhosis, ascites, and lower extremity edema who presented with acute kidney injury that resolved with IV albumin and holding diuretics?

1 Answer available

What treatments have you found most effective for cholestatic pruritus?

I have a patient with recently diagnosed primary biliary cholangitis/cirrhosis (PBC) with SSc. Her laboratory values are within normal limits, but end...

1 Answer available

Is there a role for the use of transient elastography (FibroScan) to monitor liver fibrosis in patients on long term methotrexate?

3 Answers available

How long do you treat an isolated bacterial liver abscess which has either undergone percutaneous drainage or for which an indwelling drain is placed?

3 Answers available

How do you monitor patients with incidentally found high titer anti-smooth muscle antibodies without stigmata of liver disease?

3 Answers available

How do you approach an obese patient on long-term methotrexate with normal liver tests in terms of workup for underlying fatty liver?

Would you start with a baseline ultrasound and then pursue further workup such as fibroscan if fatty liver is present, or other?

1 Answer available

Papers discussed in this category

Medizinische Klinik (Munich, Germany : 1983), 2002-11-15

[Prevalence of circulating autoantibodies in healthy individuals].

Journal for scientific research. Medical sciences, 2001 Apr

Occurence of autoantibodies in healthy Omani individuals.

Lancet (London, England), 2015-03-14

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

The New England journal of medicine, 2020 Nov 13

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.

Gastroenterology, 2015 Apr 10

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.

The New England journal of medicine, 2010 Apr 28

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Hepatology (Baltimore, Md.), 2022 Jan 24

Placebo effect on progression and regression in NASH: Evidence from a meta-analysis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2021 Jun 04

The Placebo Response in Randomized Trials in Nonalcoholic Steatohepatitis Simply Explained.

The New England journal of medicine, 2024 Feb 08

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.

Hepatology (Baltimore, Md.), 2024 Oct 18

Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance.

Lancet (London, England), 2013-02-09

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

Hepatology (Baltimore, Md.), 2018 Apr

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Clinics in liver disease, 2023 Jul 27

Chronic Hepatitis B: Treat all Who Are Viremic?

International journal of molecular sciences, 2022 Mar 13

SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection.

Primary Care

General Hepatology

Questions discussed in this category

Papers discussed in this category

Related Topics in Primary Care